Xenon reports Q2 2026 results, confirms azetukalner NDA submission on track for Q3
Xenon reported $1.2 billion in cash and said the FOS filing remains on schedule after a pre-NDA meeting with FDA.
SEC filing
Latest
2 stories
Sign inSign in2 stories
Xenon reported $1.2 billion in cash and said the FOS filing remains on schedule after a pre-NDA meeting with FDA.
SEC filing